Pernix Therapeutics Holdings Inc
Most Recent
Behind Valeant’s Top US Diversified Products in 3Q17
In 3Q17, Valeant’s Wellbutrin generated revenues of $61 million, which was ~6% lower on a year-over-year basis and 5% higher quarter-over-quarter.